1. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-2989. doi:10.1210/jc.2011-3213
2. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272(2):185-196. doi:10.1111/j.1365-2796.2012.02516.x
3. Fåhraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol. 1985;66(4):468-472.
4. Xie S-L, Chen T-Z, Huang X-L, et al. Genetic Variants Associated with Gestational Hypertriglyceridemia and Pancreatitis. PloS One. 2015;10(6):e0129488. doi:10.1371/journal.pone.0129488
5. Henneman P, Schaap FG, Rensen PCN, van Dijk KW, Smelt AHM. Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med. 2008;263(1):107-108. doi:10.1111/j.1365-2796.2007.01889.x
6. Dussaillant C, Serrano V, Maiz A, et al. APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family. BMC Med Genet. 2012;13:106. doi:10.1186/1471-2350-13- 106
7. Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):261-266. doi:10.1016/j.ejogrb.2011.07.037
8. Russi G. Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2015;53(3):283-287. doi:10.1016/j.transci.2015.11.008
9. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab. 2012;97(8):2589-2596. doi:10.1210/jc.2012-1250
10. Herrera E. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine. 2002;19(1):43-55. doi:10.1385/ENDO:19:1:43
11. Martin-Hidalgo A, Holm C, Belfrage P, Schotz MC, Herrera E. Lipoprotein lipase and hormone-sensitive lipase activity and mRNA in rat adipose tissue during pregnancy. Am J Physiol. 1994;266(61):E930-935. doi:10.1152/ajpendo.1994.266.6.E930
12. Smith JL, Lear SR, Forte TM, Ko W, Massimi M, Erickson SK. Effect of pregnancy and lactation on lipoprotein and cholesterol metabolism in the rat. J Lipid Res. 1998;39(11):2237-2249.
13. Wasfi I, Weinstein I, Heimberg M. Hepatic metabolism of [1-14C]oleate in pregnancy. Biochim Biophys Acta. 1980;619(3):471-481. doi:10.1016/0005- 2760(80)90099-5
14. Weinstock PH, Bisgaier CL, Aalto-Setälä K, et al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest. 1995;96(6):2555-2568. doi:10.1172/JCI118319
15. Péterfy M, Ben-Zeev O, Mao HZ, et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet. 2007;39(12):1483-1487. doi:10.1038/ng.2007.24
16. Sakurai T, Sakurai A, Vaisman BL, et al. Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide. J Pharmacol Exp Ther. 2016;356(2):341-353. doi:10.1124/jpet.115.229740
17. Beigneux AP, Davies BSJ, Gin P, et al. Glycosylphosphatidylinositol-anchored high- density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5(4):279-291. doi:10.1016/j.cmet.2007.02.002
18. Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294(5540):169-173. doi:10.1126/science.1064852
19. Kluger M, Heeren J, Merkel M. Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis. 2008;31(2):281-288. doi:10.1007/s10545-008-0863-4
20. Priore Oliva C, Pisciotta L, Li Volti G, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005;25(2):411-417. doi:10.1161/01.ATV.0000153087.36428.dd
21. Marçais C, Verges B, Charrière S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115(10):2862-2869. doi:10.1172/JCI24471
22. Talmud PJ. Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review. Atherosclerosis. 2007;194(2):287-292. doi:10.1016/j.atherosclerosis.2006.12.010
23. Albers K, Schlein C, Wenner K, et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. Atherosclerosis. 2014;233(1):97-103. doi:10.1016/j.atherosclerosis.2013.12.009
24. Pullinger CR, Aouizerat BE, Movsesyan I, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res. 2008;49(8):1846-1854. doi:10.1194/jlr.P800011-JLR200
25. Okazaki H, Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem. 2010;285(9):6801-6810. doi:10.1074/jbc.M109.079459
26. Takanashi M, Kimura T, Li C, et al. Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency. Arterioscler Thromb Vasc Biol. 2019;39(3):373-386. doi:10.1161/ATVBAHA.118.311931
27. Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. J Clin Invest. 2002;109(9):1125-1131.doi: 10.1172/JCI15593
28. Okazaki M, Usui S, Ishigami M, et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high- performance liquid chromatography. Arterioscler Thromb Vasc Biol. 2005;25(3):578-584. doi:10.1161/01.ATV.0000155017.60171.88
29. Carlson SE, Goldfarb S. A sensitive enzymatic method for determination of free and esterified tissue cholesterol. Clin Chim Acta Int J Clin Chem. 1977;79(3):575-582. doi:10.1016/0009-8981(77)90178-4
30. Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352-362. doi:10.1038/nrendo.2015.26
31. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 2001;291(5513):2613-2616. doi:10.1126/science.1056843
32. Kim C-W, Addy C, Kusunoki J, et al. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab. 2017;26(2):394-406.e6. doi:10.1016/j.cmet.2017.07.009
33. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. doi:10.1172/JCI23621
34. Benassayag C, Mignot TM, Haourigui M, et al. High polyunsaturated fatty acid, thromboxane A2, and alpha-fetoprotein concentrations at the human feto-maternal interface. J Lipid Res. 1997;38(2):276-286.
35. Hirano Y, Murata S, Tanaka K, Shimizu M, Sato R. Sterol regulatory element- binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway. J Biol Chem. 2003;278(19):16809-16819. doi:10.1074/jbc.M212448200
36. Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710-730. doi:10.1038/nrendo.2017.91
37. Zimmer M, Bista P, Benson EL, et al. CAT-2003: A novel sterol regulatory element- binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun. 2017;1(4):311-325. doi:10.1002/hep4.1042
38. Lee J, Goldberg IJ. Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction. J Clin Lipidol. 2008;2(1):63-66. doi:10.1016/j.jacl.2007.11.001
39. Jiang Y, Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 2017;16(1):219. doi:10.1186/s12944-017- 0612-5
40. Ramos-Román MA. Prolactin and lactation as modifiers of diabetes risk in gestational diabetes. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2011;43(9):593-600. doi:10.1055/s-0031-1284353
41. Williams C, Coltart TM. Adipose tissue metabolism in pregnancy: the lipolytic effect of human placental lactogen. Br J Obstet Gynaecol. 1978;85(1):43-46. doi:10.1111/j.1471-0528.1978.tb15824.x
42. de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United Eur Gastroenterol J. 2018;6(5):649-655. doi:10.1177/2050640618755002
43. Adiels M, Olofsson S-O, Taskinen M-R, Borén J. Overproduction of very low- density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225-1236. doi:10.1161/ATVBAHA.107.160192
44. Austin MA, Talmud PJ, Farin FM, et al. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim Biophys Acta. 2004;1688(1):1-9. doi:10.1016/j.bbadis.2003.10.003
45. Mar R, Pajukanta P, Allayee H, et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res. 2004;94(7):993-999. doi:10.1161/01.RES.0000124922.61830.F0
論文の公開元へ
